Sorafenib, in combination with conventional transarterial chemoembolization (cTACE), does not significantly improve overall survival (OS) in hepatocellular carcinoma (HCC) patients, relative to sorafenib alone, a recent study has found.
At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.
Multigene testing appears to be feasible in Asian breast cancer patients, resulting in a higher diagnostic yield and detecting pathogenic genetic mutations beyond the usual BRCA1/2 genes, according to a new Singapore study.
There appears to be no significant association between total cruciferous vegetable intake and colorectal cancer risk, but specific types of these vegetables may confer benefits against colorectal cancer, suggests a China study.
Elderly, vulnerable patients with metastatic colorectal cancer (CRC) experienced longer progression-free survival (PFS) and fewer toxicities with a reduced-dose combination chemotherapy regimen of S-1 and oxaliplatin compared with full-dose S-1 monotherapy, the phase II NORDIC9* trial showed.
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.